Patent · US Expired

Angiogenesis inhibitors

US6265403A · kind A · utility

31Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 7, 2000
Grant dateJul 24, 2001
Priority date
Expiry dateJan 7, 2020

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.